Good evening! The last full-size Kmart store in the United States is closing. On a brighter note, the Philadelphia Phillies ...

Jorgensen is set to testify before a Senate committee on Tuesday in a hearing focused on U.S. prices for its widely popular ...

The CEO of Novo Nordisk will testify in the Senate HELP Committee tomorrow about the cost of popular diabetes and weight loss ...

What the results might mean for the future of other developers in the cannabinoid receptor 1 (CB1) weight-loss arena came into question after Novo Nordisk A/S unveiled phase IIa findings with ...

As the Senate Committee on Health, Education, Labor and Pensions (HELP) gears up for a hearing tomorrow titled “Why Is Novo ...

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

Ahead of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide medications, lawmakers are ...

Novo Nordisk braced for a congressional inquiry into the high prices of weight loss and diabetes drugs, particularly Ozempic, ...

A Senate Committee on Health, Education, Labor and Pension hearing scheduled for Tuesday has all the makings of a showdown as ...

If confirmed, he would be the first person to serve in this position which was created in 2022. Novo Nordisk CEO Lars Jergensen testified on the company's pricing for its diabetes and weight loss ...

According to the Journal, the GLP-1 "pricing fight" began in late 2023, when Lilly priced Zepbound at $1,060 per month, or 20% lower than Novo Nordisk's Wegovy. Analysts told the newspaper that prices ...

Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of ...